In colon cancer cells, PKD inhibition in combination with regorafenib (an oral multikinase inhibitor with antiangiogenic activity) resulted in enhanced apoptosis through downregulating ERK, AKT, and NF-κB signaling activities [71]. This evidence concerns the gene PRKD1 and malignant colon neoplasm.